RecruitingNCT05129969

Registry Platform Ovarian and Endometrial Cancer

SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes

Sponsor

iOMEDICO AG

Enrollment

1,975 participants

Start Date

Nov 25, 2021

Study Type

OBSERVATIONAL

Conditions

Ovarian Cancer Endometrial Cancer Carcinoma Ovary Neoplasm Endometrial Neoplasms Carcinoma, Ovarian Neoplasm, Ovarian

Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This registry study collects real-world data on patients with advanced ovarian or endometrial (uterine) cancer to track how treatments work in everyday clinical practice. **You may be eligible if...** - You have advanced or metastatic ovarian, fallopian tube, or primary peritoneal cancer (FIGO stage IIb–IV) and are starting a new round of treatment - OR you have locally advanced or metastatic uterine (endometrial) cancer (FIGO stage III–IV) starting first-line treatment - You can provide signed informed consent **You may NOT be eligible if...** - You are not starting a new round of systemic (drug) treatment - You cannot or will not provide consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPhysician's choice according to patient's needs.

Routine care as per site standard.

Locations(1)

Multiple sites all over Germany

Multiple Locations, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05129969

Related Trials

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

NCT063214842 locations

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

NCT0705984573 locations

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

NCT0651561314 locations

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

NCT028307241 location

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467172 locations